UBS Group’s Johnson & Johnson JNJ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.5B | Buy |
10,209,327
+225,036
| +2% | +$52.4M | 0.37% | 33 |
|
|
2025
Q4 | $2.07B | Sell |
9,984,291
-416,000
| -4% | -$82.3M | 0.34% | 39 |
|
|
2025
Q3 | $1.93B | Sell |
10,400,291
-2,139,866
| -17% | -$367M | 0.3% | 41 |
|
|
2025
Q2 | $1.92B | Buy |
12,540,157
+631,134
| +5% | +$97M | 0.33% | 41 |
|
|
2025
Q1 | $1.97B | Sell |
11,909,023
-2,080,894
| -15% | -$326M | 0.36% | 34 |
|
|
2024
Q4 | $2.02B | Buy |
13,989,917
+2,388,470
| +21% | +$370M | 0.37% | 33 |
|
|
2024
Q3 | $1.88B | Buy |
11,601,447
+1,293,617
| +13% | +$206M | 0.41% | 33 |
|
|
2024
Q2 | $1.51B | Buy |
10,307,830
+275,196
| +3% | +$40.9M | 0.37% | 38 |
|
|
2024
Q1 | $1.59B | Buy |
10,032,634
+1,299,134
| +15% | +$207M | 0.4% | 32 |
|
|
2023
Q4 | $1.37B | Sell |
8,733,500
-984,446
| -10% | -$151M | 0.41% | 35 |
|
|
2023
Q3 | $1.51B | Buy |
9,717,946
+816,297
| +9% | +$135M | 0.52% | 25 |
|
|
2023
Q2 | $1.47B | Sell |
8,901,649
-1,904,571
| -18% | -$307M | 0.5% | 32 |
|
|
2023
Q1 | $1.67B | Sell |
10,806,220
-1,608,156
| -13% | -$260M | 0.61% | 16 |
|
|
2022
Q4 | $2.19B | Buy |
12,414,376
+1,947,285
| +19% | +$336M | 0.82% | 8 |
|
|
2022
Q3 | $1.71B | Sell |
10,467,091
-183,328
| -2% | -$31M | 0.75% | 12 |
|
|
2022
Q2 | $1.89B | Sell |
10,650,419
-261,878
| -2% | -$46.7M | 0.78% | 10 |
|
|
2022
Q1 | $1.93B | Sell |
10,912,297
-871,761
| -7% | -$148M | 0.64% | 16 |
|
|
2021
Q4 | $2.02B | Buy |
11,784,058
+388,248
| +3% | +$63.6M | 0.58% | 17 |
|
|
2021
Q3 | $1.84B | Sell |
11,395,810
-701,658
| -6% | -$120M | 0.58% | 20 |
|
|
2021
Q2 | $1.99B | Sell |
12,097,468
-259,296
| -2% | -$42.9M | 0.64% | 17 |
|
|
2021
Q1 | $2.03B | Buy |
12,356,764
+336,819
| +3% | +$54.5M | 0.67% | 15 |
|
|
2020
Q4 | $1.89B | Sell |
12,019,945
-1,047,508
| -8% | -$155M | 0.64% | 16 |
|
|
2020
Q3 | $1.95B | Sell |
13,067,453
-341,096
| -3% | -$50.5M | 0.73% | 18 |
|
|
2020
Q2 | $1.89B | Sell |
13,408,549
-187,056
| -1% | -$27.3M | 0.8% | 14 |
|
|
2020
Q1 | $1.78B | Sell |
13,595,605
-1,317,770
| -9% | -$187M | 0.84% | 11 |
|
|
2019
Q4 | $2.18B | Buy |
14,913,375
+943,414
| +7% | +$128M | 0.76% | 13 |
|
|
2019
Q3 | $1.81B | Sell |
13,969,961
-131,582
| -0.9% | -$17.3M | 0.7% | 15 |
|
|
2019
Q2 | $1.96B | Sell |
14,101,543
-969,796
| -6% | -$134M | 0.76% | 13 |
|
|
2019
Q1 | $2.11B | Buy |
15,071,339
+1,592,822
| +12% | +$213M | 0.87% | 12 |
|
|
2018
Q4 | $1.74B | Sell |
13,478,517
-593,187
| -4% | -$82.7M | 0.79% | 13 |
|
|
2018
Q3 | $1.94B | Buy |
14,071,704
+1,885,732
| +15% | +$251M | 0.77% | 12 |
|
|
2018
Q2 | $1.48B | Buy |
12,185,972
+172,006
| +1% | +$21.5M | 0.64% | 17 |
|
|
2018
Q1 | $1.54B | Sell |
12,013,966
-368,928
| -3% | -$49.9M | 0.66% | 15 |
|
|
2017
Q4 | $1.73B | Buy |
12,382,894
+1,194,851
| +11% | +$166M | 0.71% | 12 |
|
|
2017
Q3 | $1.45B | Buy |
11,188,043
+927,150
| +9% | +$123M | 0.67% | 13 |
|
|
2017
Q2 | $1.36B | Buy |
10,260,893
+2,271,145
| +28% | +$290M | 0.7% | 8 |
|
|
2017
Q1 | $995M | Buy |
7,989,748
+38,967
| +0.5% | +$4.65M | 0.54% | 20 |
|
|
2016
Q4 | $916M | Buy |
7,950,781
+118,120
| +2% | +$13.6M | 0.51% | 22 |
|
|
2016
Q3 | $925M | Sell |
7,832,661
-156,893
| -2% | -$19M | 0.55% | 20 |
|
|
2016
Q2 | $969M | Sell |
7,989,554
-306,895
| -4% | -$34.9M | 0.61% | 15 |
|
|
2016
Q1 | $898M | Sell |
8,296,449
-67,944
| -0.8% | -$7.03M | 0.6% | 14 |
|
|
2015
Q4 | $859M | Buy |
8,364,393
+1,422,909
| +20% | +$143M | 0.56% | 14 |
|
|
2015
Q3 | $648M | Sell |
6,941,484
-3,257,594
| -32% | -$315M | 0.46% | 23 |
|
|
2015
Q2 | $994M | Sell |
10,199,078
-973,204
| -9% | -$97.5M | 0.66% | 8 |
|
|
2015
Q1 | $1.12B | Sell |
11,172,282
-397,697
| -3% | -$40.4M | 0.78% | 8 |
|
|
2014
Q4 | $1.21B | Buy |
+11,569,979
| New | +$1.22B | 0.85% | 8 |
|
Other funds holding JNJ
VCM
VPM
UBS Group's JNJ Position: Q1 2026 in Review
UBS Group increased its Johnson & Johnson (JNJ) stake by 2.3% in Q1 2026, buying an estimated $52.4M and bringing the position to 10,209,327 shares worth $2.5B. The position accounts for 0.37% of the portfolio, ranked #33.
UBS Group first reported a position in JNJ in Q4 2014 and has held it in 46 quarters since. 4,616 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.
- UBS Group held 10,209,327 shares of Johnson & Johnson worth $2.5B as of Q1 2026.
- UBS Group bought 225,036 Johnson & Johnson shares in Q1 2026, an estimated $52.4M.
- Johnson & Johnson made up 0.37% of UBS Group's portfolio in Q1 2026, its #33 holding.
- UBS Group first reported a position in Johnson & Johnson in Q4 2014 and has held it in 46 quarters since.
- 4,616 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.